By Sarah Thompson , in PR PR World on November 5, 2017 .
• According to the Foundation for Women´s Cancer, every five minutes a woman will receive a gynecologic cancer diagnosis of cervical, ovarian, endometrial/uterine, or vaginal cancer
Pharma Mar SA
• PharmaMar is heavily involved in the investigation of three women's cancers (ovarian cancer, breast cancer and endometrial cancer)
PharmaMar (MCE: PHM) is pleased and honored to announce a new partnership supporting the 8th National Race to End Women's Cancer, the major awareness and fundraising event for the Foundation for Women's Cancer (FWC), which helps support research, education, and public awareness of gynecologic cancers. The Race features a 5K run and a 1-mile walk in downtown Washington, DC along historical Pennsylvania Avenue, NW, on Sunday morning, Nov. 5. Other activities held over the “End Women's Cancer Weekend” include a Survivor's Course offering patient and family resources, as well as other patient advocacy activities. Since 2009, the National Race to End Women's Cancer has brought together women and men of all ages from across the United States to celebrate survivors, honor loved ones and raise awareness. This event is attended by patients, caregivers, families, physicians and others.
According to the Foundation for Women´s Cancer, every five minutes a woman will receive a gynecologic cancer diagnosis of cervical, ovarian, endometrial/uterine, or vaginal cancer. More than 107,470 women with a gynecologic cancer will be diagnosed this year and about 31,600 will die from these cancers in 2017.
PharmaMar is heavily involved in the investigation of three women's cancers (ovarian cancer, breast cancer and endometrial cancer) and is currently awaiting data, expected early in 2018, for its pivotal Phase III trial, CORAIL, in platinum relapsed ovarian cancer with Zepsyre®. The Company is also planning on starting registrational trials, with the same molecule Zepsyre® in both BRCA2 mutated breast cancer and second line endometrial cancer during 2018.
Pascal Besman, Chief Operating Officer of PharmaMar USA, said “it is a wonderful opportunity for us to partner with the 'National Race to End Women's Cancer' given their tremendous reach in the entire women's cancer community of patients, caregivers, physicians, advocates and others, and given our extensive clinical trials for Zepsyre in three of these cancers. I am honored to represent PharmaMar as a proud participant in this important event.”
Karen Carlson, Executive Director of the Foundation for Women's Cancer, said “we're very excited and appreciative to have PharmaMar join the movement by sponsoring the 8th National Race to End Women's Cancer. We look forward to building upon our new partnership as we strive to increase public awareness of gynecologic cancer risk awareness, prevention, early detection and optimal treatment.”
About PharmaMar :
Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (lurbinectedin – PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com .
About the Foundation for Women's Cancer :
The Foundation for Women's Cancer is dedicated to increasing public awareness of gynecologic cancer risk awareness, prevention, early detection and optimal treatment. The official foundation of the Society of Gynecologic Oncology, the Foundation for Women's Cancer is a nonprofit organization that provides funding for gynecologic cancer research and training, as well as educational programs and resources. The FWC has raised more than $50 million in areas such as research, awareness, education, and outreach.
